An interactive Live Case Collaboration between
Imperial College NHS trust and Interventional Cardiology Review (ICR)
NEW USER
EXISTING ACCOUNT USERS
 from diagnosis to therapy - Radcliffe Cardiology 2016-09-04 12-41-08.png)
Livestream organised & funded by AstraZeneca & Medtronic
HAVE A QUESTION ?
To ask a question please email info@radcliffecardiology.com and we will post your question.
Performed by
Dr. Justin E Davies
Consultant Cardiologist
Imperial College NHS Trust
- Identification and confirmation of ACS diagnosis
- Evidence basis for diagnostic pathway
- Pre-procedural work-up and pharmacological regime based on the latest clinical evidence base
- Invasive diagnostic work-up
- Assessment of stenosis severity
- Revascularisation
- Take Home Messages
This live case was also streamed at the AstraZeneca booth (E100 &E150) with Professor Carlo Di Mario as special guest moderator during the ESC 2015 at the Excel Centre, London, UK. Learn more about iFR and FFR here.
The session is to inform physicians of:
- Diagnosis and recognition of acute coronary syndromes as well as risk scoring and stratification
- Understand the importance of an early invasive approach in reducing cardiac events and adverse outcomes
- Understand the role of anti-platelets in the management of patient with acute coronary syndromes
- Understand how to apply the evidence for anti platelets in clinical practice
- Experience the invasive management of a patient with acute coronary syndrome, including gaining an appreciation of how revacularisation decisions are made, how stenoses are selected for treatment and how revascularisation is performed using state of the art equipment available in catheter labs globally
This case is aimed at cardiologists, interventional cardiologists and other healthcare professionals treating ACS patients.
- Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2014;35:2541–2619. www.ncbi.nlm.nih.gov/pubmed/?term=European+Heart+Journal.+2014%3B35%3A2541%E2%80%932619
- Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Eng J Med. 2014;371:2155–2166. www.ncbi.nlm.nih.gov/pubmed/?term=New+England+Journal+of+Medicine.+2014%3B371%3A2155%E2%80%932166
- Bhatt DL, Hulot J-S, Moliterno DJ, et al. Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. Circ Res. 2014;114:1929–1943. www.ncbi.nlm.nih.gov/pubmed/?term=Circulation+Research.+2014%3B114%3A1929%E2%80%931943
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. www.ncbi.nlm.nih.gov/pubmed/?term=N+Engl+J+Med.+2009%3B361%3A1045%E2%80%931057
The Resolute Onyx stent is approved for use on CE mark countries and not available for sale in the U.S.
August 2015 - ATLAS ID: 828.602,011 - Expiry date: August 2016
